The DOI matches its Crossref record; 161 of the 162 references it cites were found in a registry or an index; none of the 112 sources its claims cite is checked for support yet.
Microglia in Alzheimer's disease
Open accessAbstract
Microglia are brain-resident myeloid cells that mediate key functions to support the CNS. Microglia express a wide range of receptors that act as molecular sensors, which recognize exogenous or endogenous CNS insults and initiate an immune response. In addition to their classical immune cell function, microglia act as guardians of the brain by promoting phagocytic clearance and providing trophic support to ensure tissue repair and maintain cerebral homeostasis. Conditions associated with loss of homeostasis or tissue changes induce several dynamic microglial processes, including changes of cellular morphology, surface phenotype, secretory mediators, and proliferative responses (referred to as an "activated state"). Activated microglia represent a common pathological feature of several neurodegenerative diseases, including Alzheimer's disease (AD). Cumulative evidence suggests that microglial inflammatory activity in AD is increased while microglial-mediated clearance mechanisms are compromised. Microglia are perpetually engaged in a mutual interaction with the surrounding environment in CNS; thus, diverse microglial reactions at different disease stages may open new avenues for therapeutic intervention and modification of inflammatory activities. In this Review, the role of microglia in the pathogenesis of AD and the modulation of microglia activity as a therapeutic modality will be discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 112 cited sources checked · 0 supported · 0 flagged
In the paper
“PRRs bind to different species of Aβ with various affinities (71).”
§ Microglia in Alzheimer's disease > Alzheimer's disease
What the sources say
- Not checked yetcites [71] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Microglial-derived immune factors can induce a so-called A1 astrocyte phenotype that contributes to neuronal death through reduced trophic support, impaired clearance capacity, and release of toxins (69).”
§ Microglia in Alzheimer's disease > Microglia activation in AD
What the sources say
- Not checked yetcites [69] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Activated microglia along with immunoglobulins and complement components are closely associated with Aβ deposits in brains from AD patients and AD mouse models (58)(59)(60)(61)(62).”
§ Microglia in Alzheimer's disease > Microglia activation in AD
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“microglia also were implicated in spreading tau aggregates through endocytosis (via phagocytosis) and exocytosis (via exosomes) in a nonsynaptic transmission pathway (68).”
§ Microglia in Alzheimer's disease > Microglia activation in AD
What the sources say
- Not checked yetcites [68] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Stewart and colleagues demonstrated that Aβ-mediated release of proinflammatory factors and neurotoxicity partially involved signaling through the CD36/ TLR4/TRL6 complex (108).”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [108] source
Strength:boosted· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“TLRs bind both fibrillar and oligomeric forms of Aβ (74).”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [74] Landreth, 2009, Toll-like receptors in Alzheimer’s disease, Curr Top Microbiol Immunol
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“recent GWAS link several immune genes, particularly complement receptor-1 (CR1), CD33, and triggering receptor expressed on myeloid cells-2 (TREM2), with increased AD risk (55).”
§ Microglia in Alzheimer's disease > Loss of inhibitory signals
What the sources say
- Not checked yetcites [55] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“These findings raise the possibility that innate immune activation may actively contribute to AD pathogenesis, rather than arising as a pure bystander reaction to amyloid deposition, as previously assumed (57).”
§ Microglia in Alzheimer's disease > Loss of inhibitory signals
What the sources say
- Not checked yetcites [57] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“a network-based integrative analysis of AD-related genes revealed that an immune/microglial gene network had the strongest association with AD neuropathology (56).”
§ Microglia in Alzheimer's disease > Loss of inhibitory signals
What the sources say
- Not checked yetcites [56] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“APOE4 expression was associated with enhanced Aβ production, driven by increasing APP expression in neurons (54).”
§ Microglia in Alzheimer's disease > Loss of inhibitory signals
What the sources say
- Not checked yetcites [54] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 35
- Probably not a substantial claim. 4
In the paper
“Increased expression of Tlr2, Tlr4, Tlr5, Tlr7, and Tlr9 mRNAs was found in Aβ plaques, and expression of Tlr2/5 was elevated in plaque-associated tissue in comparison with plaquefree tissue (107)”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [107] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Depletion of microglia suppressed tau propagation (68), suggesting that microglia actively contribute to tau pathology during AD pathogenesis.”
§ Microglia in Alzheimer's disease > Microglia activation in AD
What the sources say
- Not checked yetcites [68] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In AD pathogenesis, microglia activation may play a dual role: on one side, acute microglial activation in some experimental paradigms leads to decreased Aβ accumulation by increasing phagocytosis or clearance.”
- Also stated in: § Alzheimer's disease · plain
“chronic activation of microglia contributes to neurotoxicity and synapse loss by triggering several proinflammatory cascades.”
§ Microglia in Alzheimer's disease > Microglia activation in AD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Alzheimer's disease · plain
None of the sources cited for this claim have been checked yet.
In the paper
“activated microglia in AD show increased proliferation (63,64) and increased expression of inflammatory markers such as CD36, CD14, CD11c, MHC-II, and iNOS (65,66)”
§ Microglia in Alzheimer's disease > Microglia activation in AD
What the sources say
- Not checked yetcites [63] source
- Not checked yetcites [64] Olmos-Alonso, 2016, Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology, Brain source
- Not checked yetcites [65] Kamphuis, 2016, Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer’s disease, Biochim Biophys Acta source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In vivo imaging shows that microglia activation precedes the onset of AD (100) and is paralleled by increased levels of inflammatory markers in the cerebrospinal fluid (101)”
§ Microglia in Alzheimer's disease > Multifaceted immune activation
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“the COX-1 inhibitor naproxen was beneficial in fast decliners only; in contrast, the selective COX-2 inhibitor celecoxib was beneficial in slow decliners but harmful in the fast-progressing group.”
§ Microglia in Alzheimer's disease > Multifaceted immune activation
What the sources say
- Not checked yetcites [105] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“repeated monthly injections of CpG-ODNs reduced amyloid deposition and cerebral amyloid angiopathy, and prevented cognitive deficits.”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [116] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These findings suggested that CD14 deletion shifts microglia activation to an immunomodulatory state, possibly by blocking TLR2 signaling, which contributes to inflammation and AD pathology (115).”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [115] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In contrast to TLR4 stimulation, TLR9 stimulation decreased tau-related pathology (116).”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [116] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“COX-2 expression peaks in neurons in Braak phases 0-II (an early stage characterized by neurofibrillary changes beginning at transentorhinal regions), probably representing an adaptive response that subsequently declines (105).”
§ Microglia in Alzheimer's disease > Multifaceted immune activation
What the sources say
- Not checked yetcites [105] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“microglial activation correlated with glucose hypometabolism in AD patients (103), suggesting a link between microglial activation and synaptic dysfunction.”
§ Microglia in Alzheimer's disease > Multifaceted immune activation
What the sources say
- Not checked yetcites [103] Fan, 2015, Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease, Brain source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hence, it seems that TLR9 stimulation activates an innate immune response that benefits AD pathology without provoking inflammation.”
§ Microglia in Alzheimer's disease > Microglia proliferation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“APP/PS1dE9 mice lacking functional TRL4 showed an increase in Aβ load associated with decreased expression of IL-1β, CCL3, and CCL4 and decreased cognitive function (110), suggesting a protective role of TRL4 in amyloid clearance.”
§ Microglia in Alzheimer's disease > Toll-like receptors
What the sources say
- Not checked yetcites [110] Song, 2011, TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer’s disease, J Neuroinflammation source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“other studies have reported that inhibition of different components of complement impaired Aβ phagocytosis, resulting in elevated synapse loss.”
§ Microglia in Alzheimer's disease > Complement system
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Inhibition of microglial C3aR reduced microglial activation and augmented Aβ clearance in the brain (125), suggesting a detrimental role for complement.”
§ Microglia in Alzheimer's disease > Complement system
What the sources say
- Not checked yetcites [125] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“in the clinical phase of AD, the strong association between microglial activation and AD pathology was observed in young AD patients, but activation waned in AD patients older than 80 years (106)”
§ Microglia in Alzheimer's disease > Multifaceted immune activation
What the sources say
- Not checked yetcites [106] Hoozemans, 2011, Neuroinflammation in Alzheimer’s disease wanes with age, J Neuroinflammation source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Lian and colleagues demonstrated that Aβ induced release of C3 from astrocytes and impaired microglial Aβ phagocytosis (125).”
§ Microglia in Alzheimer's disease > Complement system
What the sources say
- Not checked yetcites [125] source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“IL-1β, a key cytokine of the innate immune response, was shown to enhance Aβ pathology (126), as well as increase tau pathology (109).”
§ Microglia in Alzheimer's disease > Cytokines
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The NLRP3 inflammasome is critical for maturation of IL-1β, and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).”
§ Microglia in Alzheimer's disease > Cytokines
What the sources say
- Not checked yetcites [131] Heneka, 2013, NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice, Nature source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Increased microglial proliferation was observed in several murine AD models (63), appearing with plaque onset and persisting for 18 months (63).”
§ Microglia in Alzheimer's disease > Microglia proliferation
What the sources say
- Not checked yetcites [63] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lawson and colleagues reported a microglial turnover rate of 0.05% at any given time in healthy brain (141), but recent data from the same group indicated a turnover rate of 0.69% (7).”
§ Microglia in Alzheimer's disease > Complement system
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“IL-10 levels are elevated in AD brain, and IL-10 overexpression in mice increased APOE expression in addition to worsening AD-related pathology and cognitive impairment (132).”
§ Microglia in Alzheimer's disease > Cytokines
What the sources say
- Not checked yetcites [132] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“microglia from TNFR-deficient 3xTgAD mice showed defective phagocytosis, highlighting the protective role of TNF-α in facilitating clearance mechanisms.”
§ Microglia in Alzheimer's disease > Cytokines
What the sources say
- Not checked yetcites [129] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Il10 deletion led to increased Aβ phagocytosis and increased CD68 reactivity in Aβ depositassociated microglia (133).”
§ Microglia in Alzheimer's disease > Cytokines
What the sources say
- Not checked yetcites [133] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Increased microglial proliferation has been described in the brains of AD patients (135), and in the prodromal stage of Parkinson disease (136), suggesting that microglial proliferation is an early event in the course of neurodegenerative diseases.”
§ Microglia in Alzheimer's disease > Microglia proliferation
What the sources say
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“TNF receptor (TNFR) deficiency in 3xTgAD mice was associated with increased amyloid deposition and enhanced tau phosphorylation (129).”
§ Microglia in Alzheimer's disease > Cytokines
What the sources say
- Not checked yetcites [129] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“TREM2 deficiency impairs microglial phagocytosis of plaques opsonized with anti-Aβ antibodies, suggesting a critical role for TREM2 in the efficacy of antibody-based therapeutics (152).”
§ Microglia in Alzheimer's disease > TREM2
What the sources say
- Not checked yetcites [152] source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“TREM2 promotes phagocytosis of apoptotic neurons, proliferation, and survival of microglia, and has been implicated in dampening TLR-induced inflammatory responses (147-151).”
§ Microglia in Alzheimer's disease > TREM2
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the CEBP/α/PU.1 pathway is involved in the regulation of monopoiesis and granulopoiesis (143, 144) and serves as a candidate for regulating proliferation in microglia.”
§ Microglia in Alzheimer's disease > Complement system
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Pharmacological inhibition of CSF1R in mice upregulated antiinflammatory mediators, including IL-4, IL-5, IL-13, and CCL9, and increased synapse and spine densities while reducing proinflammatory cytokine levels (64).”
§ Microglia in Alzheimer's disease > Complement system
What the sources say
- Not checked yetcites [64] Olmos-Alonso, 2016, Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology, Brain source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although targeting CSF1R has therapeutic potential, caution should be taken, as CSF1R haploinsufficiency was linked to adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (145).”
§ Microglia in Alzheimer's disease > Complement system
What the sources say
- Not checked yetcites [145] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“TREM2 was upregulated in CD45 hi LyC + myeloid cells surrounding the amyloid plaques, but not in parenchymal P2Y12 + microglia (155).”
§ Microglia in Alzheimer's disease > TREM2
What the sources say
- Not checked yetcites [155] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“AD risk variants in TREM2 impair the cell surface transport and expression of TREM2; some variants either impair or markedly enhance the binding of TREM2 to phospholipids, suggesting that balanced TREM2 function in AD is important to counteract disease progression (147).”
§ Microglia in Alzheimer's disease > TREM2
What the sources say
- Not checked yetcites [147] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“TREM2 deficiency eliminated plaque-associated CD45 hi LyC + myeloid cells, leading to reduced inflammation and AD-like pathology in these mice (155); however, TREM2-expressing myeloid cells were enriched in microglia processes contacting amyloid deposits in AD mice, and TREM2 deletion resulted in less compact plaques and increased dystrophic neurites.”
§ Microglia in Alzheimer's disease > TREM2
What the sources say
- Not checked yetcites [155] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Gamma oscillations arise from the activation of local circuits of excitatory and fast-spiking inhibitory neurons resonating at 20-50 Hz, and changes in gamma oscillation have been observed in neurological diseases (158).”
§ Microglia in Alzheimer's disease > Optogenics in activation of microglia
What the sources say
- Not checked yetcites [158] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Interestingly, entraining gamma oscillation at 40 Hz in 5xFAD mice induced amyloid reductions that were associated with an increase in microglial numbers and morphological changes such as soma enlargement and shortening of processes loaded with Aβ.”
§ Microglia in Alzheimer's disease > Optogenics in activation of microglia
What the sources say
- Not checked yetcites [158] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Gamma oscillations arise from the activation of local circuits of excitatory and fast-spiking inhibitory neurons resonating at 20-50 Hz, and changes in gamma oscillation have been observed in neurological diseases (158).”
§ Microglia in Alzheimer's disease > Optogenics in activation of microglia
What the sources say
- Not checked yetcites [158] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“It seems that combining human induced pluripotent stem cell (iPSC) technology (159) with recent advances in gene editing will provide new opportunities to model disease pathology that more closely resembles human AD.”
§ Microglia in Alzheimer's disease > Concluding remarks
What the sources say
- Not checked yetcites [159] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- The authors state this as an assumption: Existing mouse models do not show clear neurodegeneration or human-like tau pathology unless a tau mutation is used to induce the disease.
The authors state this as an assumption.
Aging strongly affects innate immunity and is a major risk factor for Alzheimer's disease.
“Given that age has a dramatic impact on innate immunity and represents a major risk factor for AD, more longitudinal studies need to be performed and the overall outcome of immune modulation needs to be tested in aged animals.”
The authors state this as an assumption.
Existing mouse models do not show clear neurodegeneration or human-like tau pathology unless a tau mutation is used to induce the disease.
“One limitation of current mouse models is the absence of clear neurodegeneration and human-like tau pathology unless the disease is induced by a tau mutation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuroinflammation is a key contributor to AD progression. While early immune responses may aid in the clearance of Aβ and tau aggregates, prolonged activation of microglia and astrocytes leads to chronic inflammation and the release of pro-inflammatory cytokines such as IL-1β and TNF-α, promoting neuronal damage in vulnerable brain regions like the neocortex and hippocampus [34–36].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they facilitate the clearance of Aβ through phagocytosis42, yet they can also exacerbate neurodegeneration by driving persistent neuroinflammation43.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Microglia are brain-resident innate immune effector cells and are widely thought to be the key mediators of amyloid beta clearance [14–16].”
From IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia (2019) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer's disease (AD) is characterized by the hallmark pathology comprised of widespread amyloid-β (Aβ) deposition, neurofibrillary tangle (NFT) formation, extensive neurodegeneration, and profound activation of microglia in the brain (6).”
From Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease (2017) · cites this paper as [6]
In the citing paper
“In the early stages of AD, activated microglia cause phagocytosis and clearance of pathologic Aβ and/or tau, positively affecting AD pathologies in animal models [89, 90].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [89]
In the citing paper
“Microglia both exert protective function by phagocytosing and clearing pathological protein aggregates”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [2]
In the citing paper
“Microglia phagocytose misfolded proteins, cellular debris, and dying cells to maintain homeostasis.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [2]
In the citing paper
“Reactive gliosis and neural inflammation are hallmarks of AD4,122–125.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [4]
In the citing paper
“Microglia represent innate immune cells of the CNS that play important disease-modifying roles in neurodegeneration including Alzheimer’s disease (AD) [1–4].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [3]
In the citing paper
“Data from mouse models have suggested dual roles for microglia in AD: pro-inflammatory functions that promote neurotoxicity and amyloid β (Aβ) accumulation, opposed by amyloid-clearing and neuroprotective functions [3, 4].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [3]
In the citing paper
“Aβ accumulation activates the microglia and promotes pro-inflammatory mediators’ production and impairment of their phagocytic function (232, 233).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [232]
In the citing paper
“Colocalization of reactive microglia with Aβ deposits is a hallmark of AD pathology and has been reported also in brains from AD mouse models [102,103].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [102]
In the citing paper
“Proliferation and activation of microglia in the brain, around amyloid plaques, is a prominent characteristic of AD [102].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
COX-2 treatment result conflicts with the proposed disease-stage effect
MinorThe paper places slow decliners earlier in the disease trajectory and says the selective COX-2 inhibitor celecoxib benefited them. It later suggests that blocking COX-2 in early phases may be harmful.
“the selective COX-2 inhibitor celecoxib was beneficial in slow decliners but harmful in the fast-progressing group.”
“Thus, COX-2 blockade in early phases may be harmful, whereas COX-1 inhibition (in addition to COX-2 inhibition) may be beneficial”
C5a blockade effect conflicts with the cited reference title
MinorThe text says blocking C5a increased Aβ levels and associates complement blockade with increased neurodegeneration, citing reference 124. That reference's title instead reports decreased pathology after antagonizing the C5a receptor.
“blocking of C5a (124), a downstream component of the complement cascade, increased Aβ levels in the absence of increased Aβ production, reflecting the role of complement in microglial phagocytosis.In the same studies, complement blockade was associated with increased neurodegeneration.”
“124. Fonseca MI, et al. Treatment with a C5aR antago- nist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.”
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Polazzi, E., Mengoni, I., Caprini, M., Peña‐Altamira, E., Kurtys, E., & Monti, B. (2012) · Neurosignals · doi:10.1159/000337115 · Cited by 9,023
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971 · cited 1×
“Microglial-derived immune factors can induce a so-called A1 astrocyte phenotype that contributes to neuronal death through reduced trophic support, impaired clearance capacity, and release of toxins (69).”
BackgroundThe chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875 · cited 1×
“Furthermore, while transcriptome studies have identified new markers selectively expressed on microglia, including the purinergic receptor P2Y12, transmembrane protein 119 (TMEM119), the chemokine receptor CX3CR1, and Siglec-H, other cell types may also display these markers (38, 39).”
Background
Flagged first, then by citations
1 of the 162 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1146/annurev-immunol-051116-052358 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 928
Wang, S.-Y., Fu, X., Duan, R., Wei, B., Cao, H., Yan, E., Chen, S., Zhang, Y.-D., & Jiang, T. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346468 · Cited by 53
Zhao, Q., Maci, M., Miller, M. R., Zhou, H., Zhang, F., Algamal, M., Lee, Y. F., Hou, S. S., Perle, S. J., Le, H., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00682-9 · Cited by 52
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 55
N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer’s disease
Lee, J. Y., Han, S. H., Park, M. H., Song, I., Choi, M., Yu, E., Park, C., Kim, H.-J., Kim, S. H., Schuchman, E. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16080-4 · Cited by 53
STAMarker: determining spatial domain-specific variable genes with saliency maps in deep learning
Zhang, C., Dong, K., Aihara, K., Chen, L., & Zhang, S. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad801 · Cited by 54
Zhang, L., Liu, X., Liu, D., Yu, X., Zhang, L. L., Zhu, J., Lü, S., & Liu, R. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910691 · Cited by 54
Ma, X., Chen, K., Cui, Y., Huang, G., Nehme, A., Zhang, L., Li, H., Wei, J., Liong, K., Liu, Q., et al. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24641 · Cited by 53
Noradrenaline in the aging brain: Promoting cognitive reserve or accelerating Alzheimer's disease?
Mather, M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.05.013 · Cited by 57
Exploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 51
The role of microglia in Alzheimer's disease and progress of treatment
Guan, Y., Zhang, L., Wang, S., Deng, Y., Zhou, H., Chen, D., & Zhang, L. (2022) · Ibrain · doi:10.1002/ibra.12023 · Cited by 52
Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy
Choi, I., Heaton, G. R., Lee, Y.-K., & Yue, Z. (2022) · Science Advances · doi:10.1126/sciadv.abn1298 · Cited by 54
Role of primary aging hallmarks in Alzheimer´s disease
Zhao, J., & Huai, J. (2022) · Theranostics · doi:10.7150/thno.79535 · Cited by 55
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases
Zhang, X., Wang, D., Zhang, B., Zhu, J., Zhou, Z., & Cui, L. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.001 · Cited by 53
Huang, L., Xu, D., Chen, Y., Yue, S., & Tang, Y. (2020) · Brain and Behavior · doi:10.1002/brb3.1995 · Cited by 50
Markoutsa, E., Mayilsamy, K., Gulick, D., Mohapatra, S. S., & Mohapatra, S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.008 · Cited by 52
Michael, J., Zirknitzer, J., Unger, M. S., Poupardin, R., Rieß, T., Paiement, N., Zerbe, H., Hutter‐Paier, B., Reitsamer, H. A., & Aigner, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052782 · Cited by 50
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
Brosseron, F., Kolbe, C., Santarelli, F., Carvalho, S., Antonell, A., Castro‐Gomez, S., Tacik, P., Namasivayam, A. A., Mangone, G., Schneider, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.018 · Cited by 47
Self-citationOmoluabi, T., Torraville, S. E., Maziar, A., Ghosh, A., Power, K. D., Reinhardt, C., Harley, C. W., & Yuan, Q. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12231 · Cited by 53
Bronzuoli, M. R., Facchinetti, R., Valenza, M., Cassano, T., Steardo, L., & Scuderi, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00644 · Cited by 48
Yang, M., Dang, R., Xu, P., Guo, Y., Han, W., Liao, D., & Jiang, P. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4949-x · Cited by 48
McFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
Weng, S.-T., Lai, Q., Wang, J., Zhuang, L., Cheng, L., Mo, Y., Liu, L., Zhao, Z., Zhang, Y., & Qiao, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899944 · Cited by 49
TRPM2: bridging calcium and ROS signaling pathways—implications for human diseases
Maliougina, M., & Hiani, Y. E. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1217828 · Cited by 47
In Vivo Imaging of Microglia With Multiphoton Microscopy
Hierro‐Bujalance, C., Bacskai, B. J., & García-Alloza, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00218 · Cited by 50
Metzler‐Baddeley, C., Mole, J. P., Sims, R., Fasano, F., Evans, J., Jones, D. K., Aggleton, J. P., & Baddeley, R. (2019) · Scientific Reports · doi:10.1038/s41598-018-37658-5 · Cited by 50
Ramesha, S., Rayaprolu, S., Bowen, C. A., Giver, C. R., Bitarafan, S., Nguyen, H. M., Gao, T., Chen, M. J., Nwabueze, N. V., Dammer, E. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013545118 · Cited by 47
Mishra, A., Wang, Y., Yin, F., Vitali, F., Rodgers, K. E., Soto, M., Mosconi, L., Wang, T., & Brinton, R. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101542 · Cited by 48
Secretomics to Discover Regulators in Diseases
Song, P., Kwon, Y., Joo, J., Kim, D.-G., & Yoon, J. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163893 · Cited by 48
Cell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease
Wang, X., & Li, L. (2021) · BMC Neurology · doi:10.1186/s12883-021-02407-1 · Cited by 47
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Alzheimer’s Disease: From Immune Homeostasis to Neuroinflammatory Condition
Cariddi, L. P., Mauri, M. F., Cosentino, M., Versino, M., & Marino, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113008 · Cited by 45
Microglial Activation in the Retina of a Triple-Transgenic Alzheimer’s Disease Mouse Model (3xTg-AD)
Salobrar‐García, E., Rodrigues‐Neves, A. C., Ramirez, A. I., de Hoz, R., Fernández‐Albarral, J. A., López‐Cuenca, I., Ramirez, J. M., Ambrósio, A. F., & Salazar, J. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030816 · Cited by 45
Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time
Prakash, P., Jethava, K. P., Korte, N., Izquierdo, P., Favuzzi, E., Rose, I. V. L., Guttenplan, K. A., Manchanda, P., Dutta, S., Rochet, J.-C., et al. (2021) · Chemical Science · doi:10.1039/d1sc03486c · Cited by 45
Innate Immunity and Cell Death in Alzheimer’s Disease
Lee, S., Cho, H., & Ryu, J. (2021) · ASN NEURO · doi:10.1177/17590914211051908 · Cited by 44
Wirianto, M., Wang, C., Kim, E., Koike, N., Gomez‐Gutierrez, R., Nohara, K., Escobedo, G., Choi, J. M., Han, C., Yagita, K., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101633r · Cited by 47
The complex role of inflammation and gliotransmitters in Parkinson's disease
Gopinath, A., Mackie, P. M., Phan, L. T., Tansey, M. G., & Khoshbouei, H. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105940 · Cited by 48
Zeng, Q., Li, K., Luo, X., Wang, S., Xu, X., Jiaerken, Y., Liu, X., Hong, L., Hong, H., Li, Z., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105755 · Cited by 44
Microglia phagocytic mechanisms: Development informing disease
Beiter, R. M., Sheehan, P. W., & Schafer, D. P. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102877 · Cited by 44
Lone, A., Harris, R. A., Singh, O., Betts, D. H., & Cumming, R. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-35114-y · Cited by 44
Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease
Schröder, N., Schaffrath, A., Welter, J. A., Putzka, T., Griep, A., Ziegler, P., Brandt, E., Samer, S., Heneka, M. T., Kaddatz, H., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01816-2 · Cited by 43
Self-citationZhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 46
Rejdak, K., Sienkiewicz‐Jarosz, H., Bieńkowski, P., & Álvarez, A. (2023) · Medicinal Research Reviews · doi:10.1002/med.21960 · Cited by 44
Wang, L., Zhao, H., Wang, L., Tao, Y., Du, G., Guan, W., Liu, J., Brennan, C. S., Ho, C., & Li, S. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c00498 · Cited by 45
Ham, H. J., Lee, Y. S., Yun, J., Son, D. J., Lee, H. P., Han, S., & Hong, J. T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02022-w · Cited by 42
Yang, Y., Li, N., Gao, Y., Xu, F., Chen, H., Zhang, C., & Ni, X. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03217-4 · Cited by 50
The sex-specific interaction of the microbiome in neurodegenerative diseases
Cox, L. M., Abou‐El‐Hassan, H., Maghzi, A. H., Vincentini, J., & Weiner, H. L. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146385 · Cited by 44
NLRP3 and Infections: β-Amyloid in Inflammasome beyond Neurodegeneration
Sita, G., Graziosi, A., Hrelia, P., & Morroni, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136984 · Cited by 43
Microglia heterogeneity in health and disease
Dadwal, S., & Heneka, M. T. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13735 · Cited by 48
Self-citationInflammasomes in neurodegenerative diseases
Wang, Q., Yang, S., Zhang, X., Zhang, S., Chen, L., Wang, W., Chen, N., & Yan, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00459-0 · Cited by 47
Aretz, B., Janssen, F., Vonk, J. M., Heneka, M. T., Boezen, H. M., & Doblhammer, G. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111533 · Cited by 41
Self-citationGlial Cells and Brain Diseases: Inflammasomes as Relevant Pathological Entities
Martínez, E. M., Díaz‐Muñoz, M., & Vázquez‐Cuevas, F. G. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.929529 · Cited by 43
Xiang, X., Wang, X., Wu, Y., Hu, J., Li, Y., Jin, S., & Wu, X. G. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173340 · Cited by 40
Afsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 45
Kim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051383 · Cited by 40
Ramezani, M., Komaki, A., Hashemi-Firouzi, N., Mortezaee, K., Faraji, N., & Golipoor, Z. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101804 · Cited by 40
Furosemide as a Probe Molecule for the Treatment of Neuroinflammation in Alzheimer's Disease.
Wang, Z.-Y., Vilekar, P., Huang, J.-B., & Weaver, D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00445 · Cited by 33
Increasing phagocytosis of microglia by targeting CD33 with liposomes displaying glycan ligands
Bhattacherjee, A., Daskhan, G. C., Bains, A., Watson, A. E. S., Eskandari‐Sedighi, G., Laurent, C. D. S., Voronova, A., & Macauley, M. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.010 · Cited by 41
Yang, S., Magnutzki, A., Alami, N. O., Lattke, M., Hein, T. M., Scheller, J. S., Kröger, C., Oswald, F., Yilmazer‐Hanke, D., Wirth, T., et al. (2021) · Cells · doi:10.3390/cells10102669 · Cited by 42
Kim, S., Lee, J. H., Kim, E., Reaney, M. J. T., Shim, Y. Y., & Chung, M. J. (2022) · Foods · doi:10.3390/foods11030313 · Cited by 39
Gao, C., Shen, X., Tan, Y., & Chen, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02580-1 · Cited by 48
Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia
Luca, A., Calandra, C., & Luca, M. (2018) · Aging and Disease · doi:10.14336/ad.2018.0201 · Cited by 42
Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer’s Disease: A Review
Fung, T., Iyaswamy, A., Sreenivasmurthy, S. G., Krishnamoorthi, S., Guan, X.-J., Zhu, Z., Su, C.-F., Liu, J., Kan, Y., Zhang, Y., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030705 · Cited by 43
Uchida, K. (2022) · Cells · doi:10.3390/cells11050919 · Cited by 41
Dexamethasone Induces a Specific Form of Ramified Dysfunctional Microglia
Park, M.-J., Park, H.-S., You, M., Yoo, J., Kim, S. H., & Kwon, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1156-z · Cited by 38
Honarpisheh, P., & McCullough, L. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14675 · Cited by 41
Abrogation of type-I interferon signalling alters the microglial response to Aβ1–42
Moore, Z., Mobilio, F., Walker, F. R., Taylor, J. M., & Crack, P. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-59917-0 · Cited by 38
Gao, Y., Liu, J., Wang, J., Liu, Y., Zeng, L., Ge, W., & Ma, C. (2022) · Brain Pathology · doi:10.1111/bpa.13047 · Cited by 35
Zhang, M., Qian, X., Hu, J., Zhang, Y., Lin, X., Hai, W., Shi, K., Jiang, X., Li, Y., Tang, H., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06446-3 · Cited by 38
Ferguson, C. M., Hildebrand, S. R., Godinho, B. M. D. C., Buchwald, J. E., Echeverria, D., Coles, A. H., Grigorenko, A. P., Vangjeli, L., Sousa, J., McHugh, N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13703 · Cited by 43
Self-citationSalani, F., Sterbini, V., Sacchinelli, E., Garramone, M., & Bossù, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01768 · Cited by 37
Ano, Y., Ohya, R., Takaichi, Y., Washinuma, T., Uchida, K., Takashima, A., & Nakayama, H. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190997 · Cited by 37
Allende, M. L., Zhu, H., Kono, M., Hoachlander-Hobby, L. E., Huso, V. L., & Proia, R. L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109879 · Cited by 37
Epigenetic Modulation of Microglia Function and Phenotypes in Neurodegenerative Diseases
Wang, L., Yu, C.-C., Liu, X., Deng, X., Tian, Q., & Du, Y. (2021) · Neural Plasticity · doi:10.1155/2021/9912686 · Cited by 41
Alzheimer’s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy – Bridging the Missing Link
Hu, J., & Wang, X. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.811852 · Cited by 42
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
An, Y., Li, Y., Hou, Y., Huang, S., & Pei, G. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3086010 · Cited by 37
Cory‐Slechta, D. A., Sobolewski, M., & Oberdörster, G. (2020) · Atmosphere · doi:10.3390/atmos11101098 · Cited by 36
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
Zhang, Y., & Jia, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230064 · Cited by 35
Factors affecting the GABAergic synapse function in Alzheimer’s disease: Focus on microRNAs
Rivera, J., Sharma, B., Torres, M. M., & Kumar, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102123 · Cited by 38
Yan, M., Sun, Z., Zhang, S., Yang, G., Jiang, X. Y., Wang, G., Li, R., Wang, Q., & Tian, X. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110988 · Cited by 38
Shen, Y., Liu, F., & Zhang, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117235 · Cited by 36
García‐León, J. A., Cáceres-Palomo, L., Sánchez‐Mejías, E., Mejias‐Ortega, M., Nuñez‐Diaz, C., Fernandez-Valenzuela, J. J., Sanchez-Varo, R. M., Dávila, J. C., Vitórica, J., & Gutiérrez, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186867 · Cited by 35
Song, X., Cui, Z., He, J., Yang, T., & Sun, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12168 · Cited by 35
Wang, Q., Davis, P. B., Qi, X., Chen, S. G., Gurney, M. E., Perry, G. L., Doraiswamy, P. M., & Xu, R. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00917-1 · Cited by 35
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 37
Fixemer, S., Ameli, C., Hammer, G. P., Salamanca, L., Huarte, O. U., Schwartz, C., Gérardy, J., Mechawar, N., Skupin, A., Mittelbronn, M. G. A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01342-7 · Cited by 36
Mercan, D., & Heneka, M. T. (2022) · Biology · doi:10.3390/biology11121822 · Cited by 34
Self-citationSystemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice
Lax, N., Fainstein, N., Nishri, Y., Ben‐Zvi, A., & Ben‐Hur, T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01738-z · Cited by 37
Marques, L., Johnson, A. A., & Stolzing, A. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112203 · Cited by 35
Kartalou, G.-I., Pereira, A. R. S., Endres, T., Lesnikova, A., Casarotto, P. C., Pousinha, P. A., Delanoe, K., Edelmann, E., Ċastrén, E., Gottmann, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238957 · Cited by 36
Guo, S., Cázarez‐Márquez, F., Jiao, H., Foppen, E., Korpel, N. L., Grootemaat, A. E., Liv, N., Gao, Y., van der Wel, N. N., Zhou, B., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c22434 · Cited by 35
Microglia in Alzheimer’s Disease: An Unprecedented Opportunity as Prospective Drug Target
Kulkarni, B., Martins, N. A., & Kumar, D. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02661-x · Cited by 38
Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer’s Disease
Deng, M., Yan, W., Gu, Z., Li, Y., Chen, L., & He, B. (2023) · Molecules · doi:10.3390/molecules28031486 · Cited by 38
Groh, J., Klein, D., Berve, K., West, B. L., & Martini, R. (2018) · Glia · doi:10.1002/glia.23539 · Cited by 33
The Latest Advances in the Diagnosis and Treatment of Dementia
Hafiz, R., Alajlani, L., Ali, A., Algarni, G. A., Aljurfi, H., Alammar, O. A. M., Ashqan, M. Y., & Alkhashan, A. Y. (2023) · Cureus · doi:10.7759/cureus.50522 · Cited by 41
Regulation of Microglia Identity from an Epigenetic and Transcriptomic Point of View
Eggen, B. J. L., Boddeke, E. W. G. M., & Kooistra, S. M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2017.12.010 · Cited by 34
Ahmed, H. A., & Ishrat, T. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01964-9 · Cited by 33
Qki is an essential regulator of microglial phagocytosis in demyelination
Ren, J., Dai, C., Zhou, X., Barnes, J. A., Chen, X., Wang, Y., Yuan, L., Shingu, T., Heimberger, A. B., Chen, Y., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20190348 · Cited by 36
Metadata
- Authors
- Sarlus, H., & Heneka, M. T.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Heneka, Michael T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-09-01
- Volume
- 127
- Issue
- 9
- Pages
- 3240-3249
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5669553
- OpenAlex
- W2750718695
- Semantic Scholar
- ef022dba477c27d3e9b6fce59a1f5267296be580
- Cited by
- 911
- References
- 162
- Citations by year
- 2026: 64 · 2025: 98 · 2024: 109 · 2023: 105 · 2022: 134 · 2021: 127 · 2020: 148 · 2019: 66 · 2018: 52 · 2017: 7
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- DZNE Pub (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- microglia, Alzheimer's disease, microglial activation, neuroinflammation, phagocytosis, neuroprotection, microglial receptors, neurodegeneration, brain homeostasis
- MeSH terms
- Alzheimer Disease, Animals, Brain, Central Nervous System, Complement System Proteins, Humans, Immune System, Inflammation, Macrophages, Phagocytosis, Cytokines, Microglia, Neurodegenerative Diseases, Cell Proliferation, Toll-Like Receptors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
